Welcome to our dedicated page for Ayala Pharm news (Ticker: ADXS), a resource for investors and traders seeking the latest updates and insights on Ayala Pharm stock.
The Ayala Pharmaceuticals, Inc. (ADXS) news stream captures the company’s evolution as a clinical-stage oncology developer focused on small molecule therapeutics and related platforms for rare tumors and aggressive cancers. Company announcements highlight clinical progress, strategic transactions, and regulatory milestones that shape the outlook for the ADXS symbol on the OTCQX market.
News items include detailed updates on AL102, Ayala’s investigational oral gamma secretase inhibitor for desmoid tumors, and the pivotal RINGSIDE Phase 2/3 trial. Releases discuss Phase 2 efficacy and safety data, the design of the Phase 3 registration segment, and U.S. FDA designations such as Fast Track and Orphan Drug status. Additional coverage describes the integration of aspacytarabine (BST-236), a novel anti-metabolite for unfit acute myeloid leukemia (AML), into Ayala’s pipeline following its merger with Biosight Ltd.
Investors and observers can also follow corporate and asset-level transactions through this news feed. Ayala has reported a definitive asset purchase agreement with Immunome, Inc. to acquire AL102 and AL101, and an asset purchase agreement with OS Therapies, Inc. to acquire its listeria monocytogenes-based immuno-oncology programs and related intellectual property assets, including lung and prostate cancer programs. Another key disclosure is Ayala’s Form 15 filing to deregister its common stock and suspend SEC reporting obligations.
By reviewing Ayala’s news, readers can see how the ADXS story has combined oncology drug development, mergers, and asset sales. The feed is useful for tracking clinical milestones in desmoid tumors and AML, understanding which external companies are now advancing former Ayala assets, and monitoring structural changes such as the merger with Biosight and the transition away from SEC periodic reporting. Bookmarking this page helps users quickly locate historical press releases and transaction announcements related to Ayala Pharmaceuticals and the ADXS ticker.
Advaxis has reported promising updates from its Phase 1/2 study of ADXS-503 in combination with KEYTRUDA® for non-small cell lung cancer (NSCLC). After 16 weeks, two evaluable patients showed a partial response and stable disease, suggesting potential re-sensitization to KEYTRUDA®. Preliminary biomarker results indicate activation of CD8+ T cells in all first seven patients. The trial will expand to include more patients who progressed on KEYTRUDA®, and a new part evaluating ADXS-503 as a first-line treatment is expected to commence soon.